These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17101166)

  • 1. Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor.
    Suphaphiphat P; Essex M; Lee TH
    Virology; 2007 Mar; 360(1):182-90. PubMed ID: 17101166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of amino acid substitution of the V3 and bridging sheet residues in human immunodeficiency virus type 1 subtype C gp120 on CCR5 utilization.
    Suphaphiphat P; Thitithanyanont A; Paca-Uccaralertkun S; Essex M; Lee TH
    J Virol; 2003 Mar; 77(6):3832-7. PubMed ID: 12610158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
    Cormier EG; Dragic T
    J Virol; 2002 Sep; 76(17):8953-7. PubMed ID: 12163614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
    Platt EJ; Kuhmann SE; Rose PP; Kabat D
    J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
    Foda M; Harada S; Maeda Y
    Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
    Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
    J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
    Svicher V; Alteri C; Artese A; Zhang JM; Costa G; Mercurio F; D'Arrigo R; Alcaro S; Palù G; Clementi M; Zazzi M; Andreoni M; Antinori A; Lazzarin A; Ceccherini-Silberstein F; Perno CF;
    Antivir Ther; 2011; 16(7):1035-45. PubMed ID: 22024519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
    Platt EJ; Shea DM; Rose PP; Kabat D
    J Virol; 2005 Apr; 79(7):4357-68. PubMed ID: 15767436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.
    Cormier EG; Tran DN; Yukhayeva L; Olson WC; Dragic T
    J Virol; 2001 Jun; 75(12):5541-9. PubMed ID: 11356961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional impact of HIV coreceptor-binding site mutations.
    Biscone MJ; Miamidian JL; Muchiri JM; Baik SS; Lee FH; Doms RW; Reeves JD
    Virology; 2006 Jul; 351(1):226-36. PubMed ID: 16631222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
    Gorry PR; Dunfee RL; Mefford ME; Kunstman K; Morgan T; Moore JP; Mascola JR; Agopian K; Holm GH; Mehle A; Taylor J; Farzan M; Wang H; Ellery P; Willey SJ; Clapham PR; Wolinsky SM; Crowe SM; Gabuzda D
    Virology; 2007 May; 362(1):163-78. PubMed ID: 17239419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5.
    Da LT; Wu YD
    J Chem Inf Model; 2011 Feb; 51(2):359-69. PubMed ID: 21284403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
    Pastore C; Nedellec R; Ramos A; Pontow S; Ratner L; Mosier DE
    J Virol; 2006 Jan; 80(2):750-8. PubMed ID: 16378977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
    Del Prete GQ; Leslie GJ; Haggarty B; Jordan AP; Romano J; Hoxie JA
    J Virol; 2010 Sep; 84(17):8777-89. PubMed ID: 20573813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
    Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
    J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
    Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
    J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.